Do you want to read an article? Please log in or register.
Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial
Cardiovascular Risk and Diseases
Related content
RECOMMENDED
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
doi: 10.1016/S0140-
Cardiovascular Risk and DiseasesHeart, Artery and Coronary Diseases
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
N Engl J Med.
Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK1, Sattar N, Rosengren A, Gudbjörnsdottir S
doi: 10.1056/NEJMoa1608664.
Cardiovascular Risk and Diseases
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Lancet Diabetes Endocrinol
Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, Lam CSP, Lopes RD, McMurray JJV, Pratley RE, Rosenstock J, Gerstein HC
doi: 10.1016/S2213-8587(21)00203-5
Cardiovascular Risk and Diseases
Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS
Am Heart J.
Pagidipati NJ, Zheng Y, Green JB, McGuire DK, Mentz RJ, Shah S, Aschner P, Delibasi T, Rodbard HW, Westerhout CM, Holman RR, Peterson ED, TECOS Study Group.
doi: 10.1016/j.ahj.2019.09.016.
Cardiovascular Risk and Diseases
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial
JAMA Cardiol.
Verma S, Bain SC, Buse JB, Idorn T, Rasmussen S, Ørsted DD, Nauck MA
doi: 10.1001/jamacardio.2019.3080.
RECOMMENDED
Cardiovascular Risk and Diseases
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
J Am Heart Assoc.
Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CSP, Rodgers A, Mahaffey KW, Cannon CP, Perkovic V, Jardine MJ, Neal B
doi: 10.1161/JAHA.119.014908.
Cardiovascular Risk and Diseases
Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial
JAMA.
Ray KK, Nicholls SJ, Buhr KA, Ginsberg HN, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Sweeney M, Schwartz GG, BETonMACE Investigators and Committees.
doi: 10.1001/jama.2020.3308.
Cardiovascular Risk and Diseases
Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials
Eur Heart J.
Marsico F, Paolillo S, Gargiulo P, Bruzzese D, Dell'Aversana S, Esposito I, Renga F, Esposito L, Marciano C, Dellegrottaglie S, Iesu I, Perrone Filardi P
doi: 10.1093/eurheartj/ehaa082.
Heart FailureMyocardial InfarctionThrombosis and Stroke
Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression
J Am Heart Assoc
Odutayo A, da Costa BR, Pereira TV, Garg V, Iskander S, Roble F, Lalji R, Hincapié CA, Akingbade A, Rodrigues M, Agarwal A, Lawendy B, Saadat P, Udell JA, Cosentino F, Grant PJ, Verma S, Jüni P
doi: 10.1161/JAHA.120.019918